{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:57:55Z","timestamp":1790906275759,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clinthera.2022.11.003","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T15:26:53Z","timestamp":1670513213000},"page":"1577-1587","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1804-5525","authenticated-orcid":false,"given":"Michael","family":"Korenfeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4875-2917","authenticated-orcid":false,"given":"Joe","family":"Gira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Walters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Usner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Donnenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2022.11.003_bib0001","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/archophthalmol.2012.838","article-title":"Projecting the growth of cataract surgery during the next 25 years","volume":"130","author":"Hatch","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0002","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2147\/PPA.S126283","article-title":"Evaluating the patient experience after implantation of a 0.4 mg sustained release dexamethasone intracanalicular insert (Dextenza): results of a qualitative survey","volume":"11","author":"Gira","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0003","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/112067210701700104","article-title":"Outcomes of acute postoperative inflammation after cataract surgery","volume":"17","author":"Mohammadpour","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0004","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000066189","article-title":"Corticosteroids in ophthalmology: past-present-future","volume":"216","author":"Sherif","year":"2002","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0005","first-page":"299","article-title":"Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop","volume":"7","author":"Coffey","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0006","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/polym3010193","article-title":"Recent advances in ocular drug delivery systems","volume":"3","author":"Kuno","year":"2011","journal-title":"Polymers"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0007","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0008","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/aos.12334","article-title":"Kinetics of gamma-cyclodextrin nanoparticle suspension eye drops in tear fluid","volume":"92","author":"Johannesson","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0009","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00417-005-0124-2","article-title":"Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation","volume":"244","author":"Saari","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0010","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijpharm.2017.04.010","article-title":"Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye","volume":"531","author":"Loftsson","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0011","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1600-0420.2007.00885.x","article-title":"Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye","volume":"85","author":"Sigurdsson","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0012","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1755-3768.2011.02299.x","article-title":"Topical drug delivery to the eye: dorzolamide","volume":"90","author":"Loftsson","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119452","article-title":"Effect of porcine pancreatic alpha-amylase on dexamethasone release from aqueous solution containing natural gamma-cyclodextrin","volume":"585","author":"Sripetch","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0014","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0015","first-page":"55","article-title":"Pain: clinical manual for nursing practice, Mosby Yearbook","volume":"9","author":"McCaffrey","year":"1994","journal-title":"Nurs Stand"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0016","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.2147\/OPTH.S165722","article-title":"Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy","volume":"12","author":"Shah","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0017","series-title":"Durezol [package insert]","year":"2013"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0018","series-title":"Inveltys [package insert]","year":"2018"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0019","unstructured":"Lotemax SM [package insert]. Tampa, FL: Bausch & Lomb Inc; 2020."},{"key":"10.1016\/j.clinthera.2022.11.003_bib0020","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jcrs.2018.06.056","article-title":"Submicron loteprednol etabonate ophthalmic gel 0.38% for the treatment of inflammation and pain after cataract surgery","volume":"44","author":"Fong","year":"2018","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0021","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2147\/OPTH.S210597","article-title":"Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies","volume":"13","author":"Fong","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0022","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2147\/OPTH.S185800","article-title":"Safety and efficacy of twice daily administration of KPI-121 1% for ocular inflammation and pain following cataract surgery","volume":"13","author":"Kim","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0023","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcrs.2008.09.024","article-title":"Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain","volume":"35","author":"Korenfeld","year":"2009","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0024","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2147\/OPTH.S120159","article-title":"The Prospective Health Assessment of Cataract Patients' Ocular Surface (PHACO) study: the effect of dry eye","volume":"11","author":"Trattler","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0025","first-page":"218","article-title":"Comparison of postoperative corneal changes between dry eye and non-dry eye in a murine cataract surgery model","volume":"9","author":"Kwon","year":"2016","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0026","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1016\/j.jcrs.2015.06.036","article-title":"Evaluation of dry eye after femtosecond laser-assisted cataract surgery","volume":"41","author":"Yu","year":"2015","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.clinthera.2022.11.003_bib0027","doi-asserted-by":"crossref","first-page":"e78657","DOI":"10.1371\/journal.pone.0078657","article-title":"Incidence and pattern of dry eye after cataract surgery","volume":"8","author":"Kasetsuwan","year":"2013","journal-title":"PLOS One"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003782?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291822003782?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:57:54Z","timestamp":1758963474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291822003782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0149291822003782"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.11.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2022.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}